EUVIMEDEUVIMED entdecken
Crossref

Recombinant Brevinin-1 E8.13 Peptide: Biotechnological Production And Anti-Lung Cancer Properties

Quynh Bach Thi Nhu, Huyen Ngo Thi, Trang Thu Nguyen, Manh Hai Tran, Cuong Khac Bui, Minh Tri Duong Le, Dung Bui Tri, Huyen La Thi

International Journal of Drug Delivery Technology · 13.05.2026 · 16 (27s)

DOI: 10.25258/ijddt.16.27s.90 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 13.05.2026. Verfasst von Quynh Bach Thi Nhu und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brevinin peptides belong to a family of antimicrobial peptides (amps) known for their strong antibacterial and anticancer activities. Among them, brevinin-1 e8.13 has emerged as a promising candidate for therapeutic development. This study aimed to establish an efficient recombinant expression system for brevinin-1 e8.13 in escherichia coli bl21(de3) and to evaluate its anticancer efficacy and safety profile. The gene encoding brevinin-1 e8.13 was cloned into the pet32a(+) vector and expressed as a thioredoxin (trx)-his-tagged fusion protein. Expression conditions were optimized by varying iptg concentrations (0.1–1.0 mm) and induction times (4–8 h). The recombinant protein was purified using ni²⁺ affinity chromatography, followed by factor xa cleavage and high-performance liquid chromatography (hplc). Antitumor activity was assessed in a murine lung cancer model, while toxicity was evaluated through hematological and biochemical analyses. Optimal expression was achieved with 0.5 mm iptg for 6 – 8 h, yielding 30.2 mg/l of fusion protein with a purification efficiency of 63%. The cleaved peptide reached over 90% purity as determined by hplc. In vivo experiments demonstrated that recombinant brevinin-1 e8.13 significantly reduced tumor volume without affecting body weight or causing damage to major organs, and no systemic toxicity was observed. These findings indicate that brevinin-1 e8.13 can be efficiently produced in e. Coli and exhibits potent anticancer activity with a favorable safety profile, supporting its potential as a novel therapeutic peptide for cancer treatment.

Zitieren

APA

Nhu, Q. B. T., Thi, H. N., Nguyen, T. T., Tran, M. H., Bui, C. K., Le, M. T. D., Tri, D. B., & Thi, H. L. (2026). Recombinant Brevinin-1 E8.13 Peptide: Biotechnological Production And Anti-Lung Cancer Properties. International Journal of Drug Delivery Technology, 16(27s). https://doi.org/10.25258/ijddt.16.27s.90

Vancouver

Nhu QBT, Thi HN, Nguyen TT, Tran MH, Bui CK, Le MTD, et al. Recombinant Brevinin-1 E8.13 Peptide: Biotechnological Production And Anti-Lung Cancer Properties. International Journal of Drug Delivery Technology. 2026;16(27s). doi:10.25258/ijddt.16.27s.90

BibTeX
@article{Nhu2026,
  author = {Nhu, Quynh Bach Thi and Thi, Huyen Ngo and Nguyen, Trang Thu and Tran, Manh Hai and Bui, Cuong Khac and Le, Minh Tri Duong and Tri, Dung Bui and Thi, Huyen La},
  title = {Recombinant Brevinin-1 E8.13 Peptide: Biotechnological Production And Anti-Lung Cancer Properties},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {27s},
  doi = {10.25258/ijddt.16.27s.90}
}
Kostenlos starten →